Using a new imaging agent to study a specific type of cell death in cancer
Official title: Novel applications and translation of [18F]hGTS13, a system xc- specific radiopharmaceutical
Funded at Stanford University · NIH-10934243 · Data updated 2026-11-12
This study is looking at how a special type of cell death called ferroptosis can help treat cancer, and it’s testing a new way to see how a specific transporter in cancer cells works, which could help doctors figure out which cancers might respond better to this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $411,206 |
| NIH project number | 1R01CA291644-01 |
| Project ID | NIH-10934243 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be patients with specific types of cancer that may respond to therapies targeting ferroptosis.
✕Less likely to help
Patients with non-cancerous conditions or those whose cancers do not involve the mechanisms of ferroptosis may not benefit from this research.
What this research studies
This research investigates the role of ferroptosis, a unique form of cell death, in cancer treatment. It focuses on a specific transporter in cells that affects how cancer cells respond to this type of cell death. By using a novel imaging agent, the study aims to visualize and measure the activity of this transporter in living subjects, which could help identify which cancers are more susceptible to treatment that induces ferroptosis. This approach could lead to more targeted and effective cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating cancers by selectively inducing cell death in cancer cells.
How similar studies have gone: Previous research has shown promising results in targeting ferroptosis in cancer, indicating that this approach may be effective.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Rao, Jianghong — Stanford University
- Study coordinator: Rao, Jianghong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.